biostudies-literatureUnknown11(12)Ye C<h4>Background</h4>The 5-year overall survival rate in metastatic prostate adenocarcinoma (PRAD) is extremely low. Genomic studies of PRAD have improved our understanding of disease biology. However, the role of immune checkpoint genes (ICGs) in PRAD remains unclear.<h4>Methods</h4>Univariate and multivariate analyses were used to analyze genes associated with metastasis-free survival (MFS) in The Cancer Genome Atlas (TCGA)-PRAD dataset. The expressions of <i>ADORA2A</i> and <i>TNFRSF18</i> were detected via immunohistochemical assay and real-time fluorescence quantitative PCR (RT-PCR) assay in our in-house cohort. The expression of long non-coding RNAs (lncRNAs) <i>AL139287.1</i>, <i>SLC9A3-AS1</i>, and <i>SNHG12</i> were detected via RT-PCR assay in our in-house cohort. Stepwise regressiTranslational andrology and urology1691-1705https://www.ebi.ac.uk/biostudies/studies/S-EPMC9827409biostudies-literatureA lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma.PMC9827409Zhao LYe CQiu SZhou TChen YMiao JQin SfalseA lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma.<h4>Background</h4>The 5-year overall survival rate in metastatic prostate adenocarcinoma (PRAD) is extremely low. Genomic studies of PRAD have improved our understanding of disease biology. However, the role of immune checkpoint genes (ICGs) in PRAD remains unclear.<h4>Methods</h4>Univariate and multivariate analyses were used to analyze genes associated with metastasis-free survival (MFS) in The Cancer Genome Atlas (TCGA)-PRAD dataset. The expressions of <i>ADORA2A</i> and <i>TNFRSF18</i> were detected via immunohistochemical assay and real-time fluorescence quantitative PCR (RT-PCR) assay in our in-house cohort. The expression of long non-coding RNAs (lncRNAs) <i>AL139287.1</i>, <i>SLC9A3-AS1</i>, and <i>SNHG12</i> were detected via RT-PCR assay in our in-house cohort. Stepwise regressi2022-01-01T00:00:00Z2022 Dec2025-04-04T07:22:31.175Z2025-04-04T07:22:31.175ZS-EPMC98274093663215510.21037/tau-22-711